Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6273195 | 1.00 | ABCB1 (0.56) | ABCB1KDM4E | |
| SCHEMBL4023253 | 1.00 | ABCB1 (0.56) | ABCB1KDM4E | |
| SCHEMBL9363607 | 1.00 | ABCB1 (0.56) | ABCB1KDM4E | |
| SCHEMBL481900 | 1.00 | ABCB1 (0.56) | ABCB1KDM4E | |
| SCHEMBL9371324 | 1.00 | ABCB1 (0.56) | ABCB1KDM4E | |
| Hydrazinecarboxamide SCHEMBL9398507 | 0.87 | ABCC9 (0.50) | ABCB1KDM4E | |
| SCHEMBL9767316 | 0.83 | ABCB1 (0.46) | ABCB1KDM4E | |
| SCHEMBL9040308 | 0.81 | ABCB1 (0.39) | ABCB1KDM4E | |
| SCHEMBL9040304 | 0.81 | ABCB1 (0.39) | ABCB1KDM4E | |
| SCHEMBL9765458 | 0.81 | ABCB1 (0.43) | ABCB1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3190878-A | — | — | None | — | — | JP | disclosed |
| US-20220324890-A1 | CONTROLLED-DELIVERY CROMAKALIM PRODRUGS | QLARIS BIO, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021119503-A1 | CONTROLLED-DELIVERY CROMAKALIM PRODRUGS | QLARIS BIO, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| EP-1937669-B9 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA NV (BE) | 2012-07-18 | — | — | EP | disclosed |
| EP-1937669-B1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-01 | — | — | EP | disclosed |
| US-7838553-B2 | Benzopyran derivatives as potassium channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-23 | — | — | US | disclosed |
| US-7812183-B2 | Benzopyran derivatives as potassium channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-12 | — | — | US | disclosed |
| EP-1940516-A2 | BENZOPYRAN AND PYRANOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL OPENERS | Janssen Pharmaceutica, N.V. (BE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1937669-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-02 | — | — | EP | disclosed |
| US-20070072832-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-29 | — | — | US | disclosed |
| US-5393771-A | 4-substituted benzopyran and related compounds | BRISOL-MYERS SQUIBB COMPANY (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0629619-A1 | Process for the preparation of intermediates useful in the preparation of pyranyl cyanoguanidine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-12-21 | — | — | EP | disclosed |
| EP-0624589-A2 | Intermediates useful in the preparation of pyranyl cyanoguanidine derivatives and methods of preparing same | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-11-17 | — | — | EP | disclosed |
| EP-0624581-A2 | 4-Substituted benzopyran and related compounds useful as pharmaceutical agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-11-17 | — | — | EP | disclosed |
| EP-0571822-A1 | Diazabicycloalkene derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-12-01 | — | — | EP | disclosed |
| US-5238937-A | PYRIDAZINY OR OXODIHYDROPYRIDAZINYL CHROMAN DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 1993-08-24 | — | — | US | disclosed |
| JP-H03190878-A | CHEMICAL PROCESS | BEECHAM GROUP PLC | 1991-08-20 | — | — | JP | disclosed |
| EP-0430621-A2 | Process for the preparation of chiral 3,4-epoxy benzopyrans | Beecham Group p.l.c. (GB) | 1991-06-05 | — | — | EP | disclosed |
| US-4988723-A | Hypotensive agents, vasodilation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-01-29 | — | — | US | disclosed |
| EP-0344747-A1 | Benzopyran derivatives and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324890-A1 | CONTROLLED-DELIVERY CROMAKALIM PRODRUGS | KCNJ8, KCNJ1, KCNJ11 | ABCB1 73/4885KDM4E 1321/4885 |
| US-20070072832-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | KCNJ2, KCNN1, KCNN3 | ABCB1 158/4885KDM4E 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.